CERo Therapeutics (CERO) Competitors $8.43 -0.21 (-2.43%) Closing price 04:00 PM EasternExtended Trading$8.54 +0.11 (+1.35%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. ERNA, FLGC, IMCC, PRPH, CARM, CSCI, GOVX, PHXM, LGVN, and HOOKShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Ernexa Therapeutics (ERNA), Flora Growth (FLGC), IM Cannabis (IMCC), ProPhase Labs (PRPH), Carisma Therapeutics (CARM), COSCIENS Biopharma (CSCI), GeoVax Labs (GOVX), PHAXIAM Therapeutics (PHXM), Longeveron (LGVN), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors Ernexa Therapeutics Flora Growth IM Cannabis ProPhase Labs Carisma Therapeutics COSCIENS Biopharma GeoVax Labs PHAXIAM Therapeutics Longeveron HOOKIPA Pharma CERo Therapeutics (NASDAQ:CERO) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Do analysts recommend CERO or ERNA? CERo Therapeutics currently has a consensus price target of $45.00, indicating a potential upside of 433.81%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe CERo Therapeutics is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, CERO or ERNA? CERo Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 5.42, suggesting that its share price is 442% more volatile than the S&P 500. Is CERO or ERNA more profitable? CERo Therapeutics has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets CERo TherapeuticsN/A N/A -199.71% Ernexa Therapeutics -7,652.75%N/A -682.08% Do insiders and institutionals believe in CERO or ERNA? 29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 12.7% of CERo Therapeutics shares are owned by insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, CERO or ERNA? CERo Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCERo TherapeuticsN/AN/A-$8.30MN/AN/AErnexa Therapeutics$580K20.50-$44.54M-$8.31-0.19 Does the media favor CERO or ERNA? In the previous week, Ernexa Therapeutics had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Ernexa Therapeutics and 1 mentions for CERo Therapeutics. Ernexa Therapeutics' average media sentiment score of -0.20 beat CERo Therapeutics' score of -1.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment CERo Therapeutics Negative Ernexa Therapeutics Neutral SummaryCERo Therapeutics beats Ernexa Therapeutics on 8 of the 13 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.25M$2.56B$5.74B$9.59BDividend YieldN/A1.68%4.54%4.09%P/E RatioN/A21.9730.3925.02Price / SalesN/A555.30418.87177.03Price / CashN/A176.7537.3459.16Price / Book-0.205.278.956.28Net Income-$8.30M$31.83M$3.26B$265.47M7 Day Performance1.81%-0.41%-0.19%-2.02%1 Month Performance-3.44%2.93%3.84%0.34%1 Year Performance-96.91%7.49%28.78%20.73% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics3.0513 of 5 stars$8.43-2.4%$45.00+433.8%-96.9%$3.25MN/A0.008ERNAErnexa Therapeutics0.447 of 5 stars$1.69+4.3%N/A-94.1%$11.93M$580K0.0010Earnings ReportShort Interest ↑FLGCFlora Growth3.2849 of 5 stars$18.21-11.6%$93.00+410.7%-49.3%$11.90M$59.51M0.00280News CoveragePositive NewsGap UpIMCCIM Cannabis0.9213 of 5 stars$2.60-11.3%N/A-16.2%$11.85M$39.44M0.00340Short Interest ↓PRPHProPhase Labs1.4486 of 5 stars$0.35+25.7%N/A-89.4%$11.70M$6.77M-0.28130News CoverageEarnings ReportHigh Trading VolumeCARMCarisma Therapeutics3.0514 of 5 stars$0.28+1.6%$1.93+587.5%-78.9%$11.51M$19.63M0.0020Positive NewsShort Interest ↓CSCICOSCIENS BiopharmaN/A$3.56-0.6%N/AN/A$11.26M$9.59M0.0020Positive NewsEarnings ReportGOVXGeoVax Labs1.4895 of 5 stars$0.70+2.8%$8.88+1,169.7%-90.1%$10.83M$3.95M0.0010News CoverageNegative NewsShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049LGVNLongeveron3.6544 of 5 stars$0.68-2.1%$8.67+1,173.6%-64.9%$10.55M$2.39M0.0020Earnings ReportAnalyst RevisionGap DownHOOKHOOKIPA Pharma3.1132 of 5 stars$0.85+3.0%$4.50+432.5%-83.7%$10.30M$9.35M-0.14160Gap Up Related Companies and Tools Related Companies ERNA Alternatives FLGC Alternatives IMCC Alternatives PRPH Alternatives CARM Alternatives CSCI Alternatives GOVX Alternatives PHXM Alternatives LGVN Alternatives HOOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access